Your browser doesn't support javascript.
Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020-a cross-sectional study.
Maechler, Friederike; Gertler, Maximilian; Hermes, Julia; van Loon, Welmoed; Schwab, Frank; Piening, Brar; Rojansky, Shay; Hommes, Franziska; Kausch, Franka; Lindner, Andreas K; Burock, Susen; Rössig, Heike; Hartmann, Claudia; Kirchberger, Valerie; Thieme, Alexander; Behnke, Michael; Gastmeier, Petra; Mockenhaupt, Frank P; Seybold, Joachim.
  • Maechler F; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany. Electronic address: friederike.maechler@charite.de.
  • Gertler M; Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hermes J; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • van Loon W; Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schwab F; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Piening B; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Rojansky S; Microsoft Corporation, Berlin, Germany.
  • Hommes F; Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kausch F; Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Lindner AK; Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Burock S; Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Rössig H; Medical Directorate, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hartmann C; Medical Directorate, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Kirchberger V; Medical Directorate, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Thieme A; Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Behnke M; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Gastmeier P; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Mockenhaupt FP; Institute of Tropical Medicine and International Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Seybold J; Medical Directorate, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Clin Microbiol Infect ; 26(12): 1685.e7-1685.e12, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-722869
ABSTRACT

OBJECTIVE:

In Berlin, the first public severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing site started 1 day after the first case in the city occurred. We describe epidemiological and clinical characteristics and aim at identifying risk factors for SARS-CoV-2 detection during the first 6 weeks of operation.

METHODS:

Testing followed national recommendations, but was also based on the physician's discretion. We related patient characteristics to SARS-CoV-2 test positivity for exploratory analyses using a cross-sectional, observational study design.

RESULTS:

Between 3 March and 13 April 2020, 5179 individuals attended the site (median age 34 years; interquartile range 26-47 years). The median time since disease onset was 4 days (interquartile range 2-7 days). Among 4333 persons tested, 333 (7.7%) were positive. Test positivity increased up to 10.3% (96/929) during the first 3 weeks and then declined, paralleling Germany's lock-down and the course of the epidemic in Berlin. Strict adherence to testing guidelines resulted in 10.4% (262/2530) test positivity, compared with 3.9% (71/1803) among individuals tested for other indications. A nightclub was a transmission hotspot; 27.7% (26/94) of one night's visitors were found positive. Smell and/or taste dysfunction indicated coronavirus disease 2019 (COVID-19) with 85.6% specificity (95% CI 82.1%-88.1%). Four per cent (14/333) of those infected were asymptomatic. Risk factors for detection of SARS-CoV-2 infection were recent contact with a positive case (second week after contact, OR 3.42; 95% CI 2.48-4.71), travel to regions of high pandemic activity (e.g. Austria, OR 4.16; 95% CI 2.48-6.99), recent onset of symptoms (second week, OR 3.61; 95% CI 1.87-6.98) and an impaired sense of smell/taste (4.08; 95% CI 2.36-7.03).

CONCLUSIONS:

In this young population, early-onset presentation of COVID-19 resembled flu-like symptoms, except for smell and/or taste dysfunction. Risk factors for SARS-CoV-2 detection were return from regions with high incidence and contact with confirmed SARS-CoV-2 cases, particularly when tests were administered within the first 2 weeks after contact and/or onset of symptoms.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Carrier State / COVID-19 Testing / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Carrier State / COVID-19 Testing / COVID-19 Type of study: Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2020 Document Type: Article